Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech bought 150,000 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was purchased at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the transaction, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Radius Health, Inc. (NASDAQ:RDUS) traded up 3.468% on Friday, reaching $35.355. The company had a trading volume of 1,214,222 shares. The company has a 50-day moving average of $43.75 and a 200 day moving average of $40.42. The stock’s market cap is $1.54 billion. Radius Health, Inc. has a one year low of $31.58 and a one year high of $59.88.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by $0.23. The firm had revenue of $0.98 million during the quarter, compared to the consensus estimate of $1.96 million. During the same quarter in the prior year, the company posted ($1.01) EPS. On average, equities research analysts predict that Radius Health, Inc. will post ($5.51) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/growth-n-v-biotech-acquires-150000-shares-of-radius-health-inc-nasdaqrdus-stock/1472766.html.

RDUS has been the subject of several research reports. Jefferies Group LLC set a $34.00 target price on Radius Health and gave the stock a “hold” rating in a research report on Monday, June 5th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. BidaskClub upgraded Radius Health from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the stock a “buy” rating in a research report on Monday, May 22nd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $53.60.

A number of large investors have recently added to or reduced their stakes in RDUS. C WorldWide Group Holding A S raised its stake in Radius Health by 0.6% in the first quarter. C WorldWide Group Holding A S now owns 7,397 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 43 shares during the period. Envestnet Asset Management Inc. raised its stake in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 46 shares during the period. Principal Financial Group Inc. raised its stake in Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 180 shares during the period. Sei Investments Co. raised its stake in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 690 shares during the period. Finally, OppenheimerFunds Inc. raised its stake in Radius Health by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock worth $11,658,000 after buying an additional 831 shares during the period.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.